MSI-H CANCER
Clinical trials for MSI-H CANCER explained in plain language.
Never miss a new study
Get alerted when new MSI-H CANCER trials appear
Sign up with your email to follow new studies for MSI-H CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests an experimental drug called MOMA-341, taken as a pill, for people with advanced solid tumors that have specific genetic features (MSI-H or dMMR). The study includes up to 132 adults whose cancer has not responded to prior treatments. The main goal is …
Matched conditions: MSI-H CANCER
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New daily pill aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests an experimental daily pill, NDI-219216, in about 134 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Participants will take the pill daily, visit the …
Matched conditions: MSI-H CANCER
Phase: PHASE1, PHASE2 • Sponsor: Nimbus Wadjet, Inc. • Aim: Disease control
Last updated May 17, 2026 01:59 UTC